• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    1/22/26 4:15:46 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDT alert in real time by email
    false 0001896212 0001896212 2026-01-16 2026-01-16 0001896212 CDT:CommonStock0.0001ParValuePerShareMember 2026-01-16 2026-01-16 0001896212 CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2026-01-16 2026-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 16, 2026

     

    CDT Equity Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41245   87-3272543
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)

     

    4851 Tamiami Trail North, Suite 200, Naples, FL   34103
    (Address of principal executive offices)   (Zip Code)

     

    (646) 491-9132

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   CDT   The Nasdaq Stock Market LLC
    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock   CDTTW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Equity Purchase Agreement

     

    On January 16, 2026, CDT Equity Inc. (the “Company”), entered into a directed stock purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) relating to an equity line of credit facility (the “ELOC”). Pursuant to the Purchase Agreement, the Company will have the right from time to time at its option to sell to the Purchaser up to $25 million of the Company’s common stock, par value $0.0001 per share (“Common Stock”), subject to certain customary conditions and limitations set forth in the Purchase Agreement, including that (i) the Purchaser shall not be obligated to purchase or acquire any shares of Common Stock that would result in its beneficial ownership exceeding 9.99% of the Company’s then-outstanding voting power and (ii) the Purchaser shall not be obligated to purchase shares of Common Stock if the volume weighted average price for the Common Stock on an Advance Notice Date (as defined in the Purchase Agreement) is less than $1.35 (the “Floor Price”). On each six-month anniversary of the Purchase Agreement, the Floor Price will adjust to the lower of the Nasdaq Official Closing Price for the day prior to the relevant adjustment date, and the average of the Nasdaq Official Closing Price for the five-day period prior to the relevant adjustment date.

     

    Pursuant to the Purchase Agreement, the Company will have the right, but not the obligation, to direct the Purchaser to purchase shares of Common Stock at its sole discretion from time to time until the earlier of (i) the first day of the month following the 36-month period after the effective date of the Purchase Agreement; and (ii) such time as $25 million of Common Stock has been sold to the Purchaser pursuant to the Purchase Agreement. To initiate a purchase, the Company must deliver written notice to the Purchaser before trading begins on any trading day. The purchase price of the shares (the “Share Price”) will be determined based on the timing and conditions of an advance notice (each, an “Advance Notice”). The purchase price pursuant to an Advance Notice shall be 97% of the lowest dollar volume-weighted average price (“VWAP”) of the Company’s Common Stock in the ten trading days immediately prior to closing date of a particular transaction associated with an advance notice, provided that if such average VWAP is below $2.00, the purchase price shall be 95% of the VWAP and if such average VWAP is below $1.00, the purchase price shall be 94% of the VWAP. Notwithstanding such, without the consent of the Purchaser, no closing shall exceed $750,000 or 100% of the product of the daily trading volume of any trading day and the VWAP of that trading day.

     

    Sales of Common Stock to the Purchaser under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading price of shares of Common Stock and determinations by the Company regarding the use of proceeds of such sales. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and prices at which, the shares of Common Stock are sold to the Purchaser. The Company expects to use the proceeds from any sales under the Purchase Agreement for working capital and general corporate purposes.

     

    Under the terms of the Purchase Agreement, the Company has agreed not to engage in any other “at the market offering” or “equity line of credit” transaction during the term of the Purchase Agreement.

     

    As consideration for the Purchaser’s irrevocable commitment to purchase the shares of Common Stock upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement, the Company agreed to issue 204,031 shares of Common Stock to the Purchaser (the “Commitment Shares”). The Commitment Shares shall be payable on the earlier of (i) April 16, 2026 and (ii) the date the Resale Registration Statement (as defined below) is effective.

     

    The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations by each party. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of the Purchase Agreement and as of specific dates, were solely for the benefit of the parties to such agreements and are subject to certain important limitations. The foregoing description of the Purchase Agreement is subject to and qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is included as Exhibit 10.1 hereto, and the terms of which are incorporated herein by reference.

     

     

     

     

    Registration Rights Agreement

     

    In connection with the Company’s entry into the Purchase Agreement, the Company also entered into a registration rights agreement with the Purchaser (the “Registration Rights Agreement”), pursuant to which the Company agreed to register the resale (the “Resale Registration Statement”), pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), of the shares of Common Stock that may be sold to the Purchaser under the ELOC and the Commitment Shares. The Company has an obligation to file the Resale Registration Statement with the Securities and Exchange Commission by the 15th calendar day following the Effective Date, and cause the Resale Registration Statement be declared effective by the Securities and Exchange Commission within 45 days of the initial filing date of the Resale Registration Statement.

     

    The foregoing description of the Registration Rights Agreement is subject to and qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is included as Exhibit 10.2 hereto, and the terms of which are incorporated herein by reference.

     

    Item 3.02. Unregistered Sales of Equity Securities.

     


    The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein. The issuance of the Commitment Shares and the shares of Common Stock the Company may sell under the Purchase Agreement will initially be made pursuant to Section 4(a)(2) under the Securities Act in reliance on representations made by the Purchaser to the Company in the Purchase Agreement.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1*   Equity Purchase Agreement, dated January 16, 2026, by and among the Registrant and the Purchaser
    10.2*   Registration Rights Agreement, dated January 16, 2026, by and among the Registrant and the Purchaser
    104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CDT EQUITY INC.
         
    January 22, 2026 By: /s/ Andrew Regan
      Name: Andrew Regan
      Title: Chief Executive Officer

     

     

    Get the next $CDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDT
    SEC Filings

    View All

    SEC Form S-8 filed by CDT Equity Inc.

    S-8 - CDT Equity Inc. (0001896212) (Filer)

    1/30/26 9:06:13 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by CDT Equity Inc.

    S-3 - CDT Equity Inc. (0001896212) (Filer)

    1/29/26 7:26:45 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - CDT Equity Inc. (0001896212) (Filer)

    1/22/26 4:15:46 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has engaged NJS Foresight Bio-Advisory, LLC to identify, source and support the execution of out-licensing opportunities for selected assets within its solid-form patent portfolio. The engagement is intended to expand CDT's commercial reach and accelerate potential licensing and royalty-based transactions. NJS Foresight Bio-Advisory, LLC brings more than 20 years of out-licensing experience and has completed numerous successful licensing agreements across the biotechnology and pharmaceutical sectors. The firm's principal, Dr. Nicholas

    1/2/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. Announces Reverse Stock Split

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), announces that its board of directors has approved a 1-for-8 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios, at the Company's Special Meeting of Stockholders held on May 5, 2025. The directors expect that the reverse stock split will increase the amount of funds the Company might be able to raise to execute its strategy. The reverse stock split will become effective on October 10, 2025, at 5:

    10/9/25 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Regan Andrew was granted 224,800 shares (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    12/22/25 4:05:28 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Regan Andrew was granted 1,120,000 shares, increasing direct ownership by 2,545,455% to 1,120,044 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    9/22/25 4:29:05 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Bligh James was granted 480,000 shares, increasing direct ownership by 2,000,000% to 480,024 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    9/19/25 4:46:26 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Leadership Updates

    Live Leadership Updates

    View All

    Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

    Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in

    11/19/24 4:30:00 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals to Join Russell 3000® Index

    SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat

    6/13/24 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

    Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide

    3/19/24 7:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Financials

    Live finance-specific insights

    View All

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

    Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP

    7/7/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

    Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder valueSynergistic combination therapies under evaluation could redefine treatment standards in veterinary and human applications NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWS

    6/4/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/18/24 4:15:06 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Conduit Pharmaceuticals Inc.

    SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/11/24 6:01:23 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care